Pharmacy Disclosure Log 2024

1. Acute Myeloid Leukaemia Response 256
2. Allogeneic Stem Cell Transplants Response 268
3. Allogeneic Stem Cell Transplants Response 268 - Attachment
4. Alpha-1 Proteinase-Inhibitor Response 095
5. Ammonia Blood Testing Response 406
6. Asthma Response 235
7. Biliary Tract and Non-Small Cell Lung Cancer Treatment Response 244
8. Biologic and Targeted Medications Response 215
9. Biologic Medicines in Gastroenterology Response 362
10. Biologic Medicines in Dermatology Response 022
11. Biologic Medicines in Gastroenterology Response 076
12. Biologic and Biosimilar Response 295
13. Biologic Medicines in Dermatology Response 293
14. Blood Monitoring Devices Response 294
15. Blood Test Volumes Response 270
16. Breast Cancer Response 110
17. Cancer Treatment using Specified Products Response 379
18. Colorectal Cancer Response 169
19. Colorectal Cancer Response 430
20. Diffuse Large B Cell Lymphoma Response 425
21. Endometrial Cancer Response 427
22. GCA and HS Response 038
23. GCA and HS Response 038-Attachment1
24. Giant Cell Arteritis Response 301
25. Giant Cell Arteritis Response 8427 -Attachment
26. Haematology and Immunoglobulin Treatments Response175
27. Haematology and Immunoglobulin Treatments Response 414
28. Immunology Response 144
29. Intra-Vitreal Injections or Implants Response 028
30. Intra-Vitreal Injections or Implant Response 305
31. Intravitreal Treatments for any Eye Condition Response 089
32. Intra-Vitreal Treatments Response 391
33. Lung Cancer Response 120
34. Metastatic Renal Cell Carcinoma Response 225
35. Migraine Response 188
36. Migraine Response 371
37. Multiple Myeloma Response 273
38. Myelofibrosis Response 165
39. Myelofibrosis Response 165 -Attachment 1
40. Myelofibrosis Response 418
41. Myelofibrosis Response 418 - Attachment
42. Non-Small Cell Lung Cancer Response 374
43. Oncology Breast Cancer Response 358
44. Oncology Supplemental Response 180
45. Oncology Supplemental Response 438
46. Oncology Treatment by Therapies Response 292
47. Patients Treated for any Disease Response 337
48. Patients Treated for any Disease Response 337 - Attachment
49. Pharmaceutical Companies Response 381
50. Posology of Enoxaparin Response 434
51. Prescription CBPMs Response 112
52. Renal Cell Carcinoma Response 192
53. Renal Cell Carcinoma Response 192 - Attachment
54. Renal Cell Carcinoma Response 383
55. Renal Cell Carcinoma Request 383 - Attachment
56. Rheumatology Department Response 008
57. Treatment with Specified Products Response 047
58. Treatment of Cancers Response 212
59. Treatment of Dermatological Conditions Response 219
60. Urothelial and Endometrial Cancer Response 247

 

 

• Share:
• Facebook
• Twitter
• LinkedIn